Skip to main content
GOODWILL E-HEALTH INFO CO., LTD. logo

GOODWILL E-HEALTH INFO CO., LTD. — Investor Relations & Filings

Ticker · 688246 ISIN · CNE1000055V0 Shanghai Stock Exchange Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 569 across all filing types
Latest filing 2022-12-29 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688246

About GOODWILL E-HEALTH INFO CO., LTD.

https://www.bjgoodwill.com/

Goodwill E-Health Info Co., Ltd. specializes in the development and implementation of comprehensive healthcare information technology solutions. The company focuses on digitalizing clinical workflows through its core offerings, which include advanced Hospital Information Systems (HIS), Electronic Medical Record (EMR) systems, and Clinical Information Systems (CIS). Its product suite is designed to enhance hospital management efficiency, improve patient safety, and facilitate data-driven clinical decision-making. Goodwill E-Health also provides regional healthcare information platforms that enable data sharing and interoperability across multiple medical institutions. By leveraging big data and cloud computing, the company supports the construction of smart hospitals and integrated healthcare networks, catering primarily to large-scale medical centers and public health organizations seeking digital transformation.

Recent filings

Filing Released Lang Actions
嘉和美康关于向激励对象授予预留部分股票期权与限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from 嘉和美康（北京）科技股份有限公司 regarding the granting of reserved stock options and restricted stocks to incentive recipients. It includes specifics about the number of shares/options granted, the conditions for granting, the approval process, legal and financial advisor opinions, accounting treatment, and the impact on company performance. The document is not a full annual or interim financial report, nor is it a simple announcement of a report publication. It is not related to board changes, earnings releases, or legal proceedings. The content focuses on the company's stock incentive plan and the granting of equity awards to employees and management, which is a capital/financing activity related to equity compensation. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is a substantive filing, not a brief announcement or regulatory filing fallback.
2022-12-29 Chinese
嘉和美康关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 嘉和美康 (Jiahe Meikang) regarding the use of temporarily idle raised funds for cash management. It details the board and supervisory committee approvals, investment purpose, investment products, limits, risk analysis, and independent opinions. The document is a formal disclosure about the company's financing fund usage and management, not a financial report or audit. It does not contain financial statements or quarterly/yearly results. It is a regulatory announcement about capital usage and compliance with securities regulations. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 3293 characters, which is typical for an announcement rather than a full report.
2022-12-29 Chinese
嘉和美康2022年股票期权与限制性股票激励计划预留授予部分激励对象名单
Remuneration Information Classification · 95% confidence The document is a detailed listing of stock option and restricted stock incentive allocations to various individuals within the company, including board members and key personnel. It includes specific numbers of stock options and restricted shares granted, percentages relative to total stock options and company share capital, and notes on eligibility and limits. The document is dated December 30, 2022, and is issued by the company's board. This type of document is related to executive and employee compensation through stock incentives, which falls under Remuneration Information filings. It is not an announcement of a report, nor a general regulatory filing, but a detailed disclosure of stock-based compensation allocations.
2022-12-29 Chinese
北京市中伦律师事务所关于嘉和美康（北京）科技股份有限公司2022年股票期权与限制性股票激励计划预留部分授予事项的法律意见书
Regulatory Filings
2022-12-29 Chinese
嘉和美康第四届监事会第六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the sixth meeting of the fourth Supervisory Board of 嘉和美康（北京）科技股份有限公司. It details approvals related to stock option grants, use of idle raised funds for cash management, and use of excess raised funds to repay bank loans and supplement working capital. The document includes voting results and compliance with relevant laws and regulations. It is not a full financial report, earnings release, or management discussion, but rather a formal meeting resolution announcement. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is also not a Board/Management change announcement but a Supervisory Board meeting resolution. Given the nature of the content and the formal announcement style, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length is short (2145 characters), and it is not merely announcing a report publication but providing substantive meeting resolutions. Therefore, the classification is RNS with high confidence.
2022-12-29 Chinese
华泰联合证券有限责任公司关于嘉和美康（北京）科技股份有限公司使用部分超募资金归还银行贷款和永久补充流动资金的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from the sponsor institution (华泰联合证券有限责任公司) regarding the use of part of the over-raised funds by 嘉和美康（北京）科技股份有限公司 to repay bank loans and supplement permanent working capital. It references regulatory rules and approvals related to the use of raised funds, details the amount of funds raised, their intended use, and confirms compliance with relevant laws and procedures. The document is not a full financial report but rather a regulatory compliance and verification statement related to capital use. It does not contain financial statements or earnings data, nor is it a brief announcement or a proxy statement. It fits best as a Regulatory Filing (RNS) because it is a compliance and regulatory disclosure document that does not fit other specific categories like Capital/Financing Update (CAP) or Annual Report (10-K). The document length is under 5,000 characters and is a formal opinion letter, not a report itself.
2022-12-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.